Role of gastrointestinal hormones in postprandial reduction of bone resorption
- PMID: 14672353
- DOI: 10.1359/jbmr.2003.18.12.2180
Role of gastrointestinal hormones in postprandial reduction of bone resorption
Abstract
Collagen type I fragments, reflecting bone resorption, and release of gut hormones were investigated after a meal. Investigations led to a dose escalation study with glucagon like peptide-2 (GLP-2) in postmenopausal women. We found a dose-dependent effect of GLP-2 on the reduction of bone resorption.
Introduction: The C-terminal telopeptide region of type I collagen as measured in serum (s-CTX) can be used to assess bone resorption. This marker of bone resorption has a significant circadian variation that is influenced by food intake. However, the mediator of this variation has not been identified.
Materials and methods: We studied the release of the gut hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-2 (GLP-2; a representative of the intestinal proglucagon-derived peptides) after ingestion of glucose, fat, protein, and fructose, as well as their effects after parenteral administration in relation to bone turnover processes in healthy volunteers. Furthermore, we studied the effect on bone turnover of a single subcutaneous injection of GLP-2 in four different dosages (100, 200, 400, or 800 microg GLP-2) or placebo in 60 postmenopausal women (mean age, 61 +/- 5 years).
Results: All macronutrients significantly (p < 0.05) reduced bone resorption as assessed by s-CTX (39-52% from baseline), and only the glucagon-like peptides were secreted in parallel. Parenteral administration of GIP and GLP-1 did not result in a reduction of the s-CTX level, whereas GLP-2 caused a statistically significant and dose-dependent reduction in the s-CTX level from baseline compared with placebo (p < 0.05). Urine DPD/creatinine, a marker of bone resorption, was significantly reduced by 25% from baseline in the 800-microg GLP-2 group (p < 0.01). An area under the curve (AUC(0-8h)) analysis for s-CTX after GLP-2 injection confirmed the dose-dependent decrease (ANOVA, p = 0.05). The s-osteocalcin level was unaffected by the GLP-2 treatment.
Conclusion: These studies exclude both GIP and GLP-1 as key mediators for the immediate reduction in bone resorption seen after a meal. The dose-dependent reduction of bone resorption markers found after subcutaneous injection of GLP-2 warrants further investigation into the mechanism and importance of GLP-2 for the bone turnover processes.
Similar articles
-
Four-month treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD.Bone. 2009 Nov;45(5):833-42. doi: 10.1016/j.bone.2009.07.008. Epub 2009 Jul 22. Bone. 2009. PMID: 19631303 Clinical Trial.
-
Bone resorption is decreased postprandially by intestinal factors and glucagon-like peptide-2 is a possible candidate.Scand J Gastroenterol. 2007 Jul;42(7):814-20. doi: 10.1080/00365520601137272. Scand J Gastroenterol. 2007. PMID: 17558904
-
Disassociation of bone resorption and formation by GLP-2: a 14-day study in healthy postmenopausal women.Bone. 2007 Mar;40(3):723-9. doi: 10.1016/j.bone.2006.09.025. Epub 2006 Nov 1. Bone. 2007. PMID: 17081815 Clinical Trial.
-
The biology of incretin hormones.Cell Metab. 2006 Mar;3(3):153-65. doi: 10.1016/j.cmet.2006.01.004. Cell Metab. 2006. PMID: 16517403 Review.
-
What do we know about the secretion and degradation of incretin hormones?Regul Pept. 2005 Jun 15;128(2):117-24. doi: 10.1016/j.regpep.2004.06.007. Regul Pept. 2005. PMID: 15780431 Review.
Cited by
-
Effect of gut hormones on bone metabolism and their possible mechanisms in the treatment of osteoporosis.Front Pharmacol. 2024 Apr 25;15:1372399. doi: 10.3389/fphar.2024.1372399. eCollection 2024. Front Pharmacol. 2024. PMID: 38725663 Free PMC article. Review.
-
Gut-Derived Peptide Hormone Analogues and Potential Treatment of Bone Disorders in Obesity and Diabetes Mellitus.Clin Med Insights Endocrinol Diabetes. 2024 Mar 13;17:11795514241238059. doi: 10.1177/11795514241238059. eCollection 2024. Clin Med Insights Endocrinol Diabetes. 2024. PMID: 38486712 Free PMC article. Review.
-
Effects of Incretin Therapy on Skeletal Health in Type 2 Diabetes-A Systematic Review.JBMR Plus. 2023 Sep 25;7(11):e10817. doi: 10.1002/jbm4.10817. eCollection 2023 Nov. JBMR Plus. 2023. PMID: 38025038 Free PMC article. Review.
-
Bone resorption and incretin hormones following glucose ingestion in healthy emerging adults.J Clin Transl Endocrinol. 2023 Feb 6;31:100314. doi: 10.1016/j.jcte.2023.100314. eCollection 2023 Mar. J Clin Transl Endocrinol. 2023. PMID: 36845829 Free PMC article.
-
Bone Turnover Markers: Basic Biology to Clinical Applications.Endocr Rev. 2023 May 8;44(3):417-473. doi: 10.1210/endrev/bnac031. Endocr Rev. 2023. PMID: 36510335 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources